Last Updated on December 31, 2023 by The Health Master
USFDA Inspection Process
USFDA Inspection Process: In a first for the agency, a distinguished delegation from the US Food & Drug Administration (USFDA), headed by Commissioner Dr. Robert M. Califf, paid a visit to Divi’s Laboratories‘ manufacturing facilities.
Divi’s Laboratories is a renowned active pharmaceutical ingredient (API) producer with headquarters in Hyderabad.
This landmark event marked a significant stride in strengthening international pharmaceutical collaborations.
Exploring Divi’s Laboratories
The delegation, which included Dr. Sarah McMullen, USFDA’s India Country Director, meticulously explored Divi’s Laboratories’ state-of-the-art production units located in Choutuppal on the outskirts of Hyderabad, Telangana.
During the visit, Divi’s Laboratories showcased its expansive production capabilities, underpinned by cutting-edge automation technologies.
Emphasizing a steadfast commitment to innovation, the company highlighted its pivotal role in investing in emerging technologies to ensure a steady supply of premium-quality APIs.
Global Impact
A key highlight of the visit was the interaction between the USFDA delegation and the top-tier management of Divi’s Laboratories.
With a reach extending to over 100 countries, the company plays a crucial role in the global pharmaceutical supply chain by providing APIs of the highest caliber.
Key Discussion Points
The agenda of the USFDA delegation’s visit spanned a diverse array of pivotal topics, underscoring the evolving landscape of the API industry.
Discussions encompassed the seamless integration of new technologies, sustainable practices in chemistry, elevating manufacturing standards, and securing the consistent availability of APIs.
This multifaceted conversation shed light on the dynamic nature of the pharmaceutical sector and its ongoing efforts to meet global healthcare demands.
Dr. Kiran S Divi’s Perspective
Dr. Kiran S Divi, the CEO of Divi’s Laboratories Limited, expressed pride in the company’s pivotal role during this crucial visit.
He emphasized the company’s capability to deliver substantial quantities of APIs within compressed timelines.
Dr. Divi conveyed the company’s eagerness to sustain active engagement in addressing critical issues that resonate across the worldwide pharmaceutical industry.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA issued Positive EIR to Gland Pharma: Hyderabad
Anti-TB Drugs: Urgent appeal to address critical shortage in India
India’s Pharma-MedTech Sector: New Policy and Scheme unveiled for transforming
USFDA approval granted for Icosapent Ethyl capsules
Quality Control in Pharma: Understanding the Significance of Dissolution Test
Drug Recall: Sucralfate Oral Suspension recalled due to this reason
Antimicrobial Resistance in India: The Alarming Rise and Potential Solutions –ICMR
Govt Job: CDSCO Recruitment 2023 – Lucrative Opportunity
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
